Jones W. Bryan Net Worth

The estimated Net Worth of Jones W. Bryan is at least $146 mil dollars as of 4 August 2017. Jones Bryan owns over 4,700 units of Supernus Pharmaceuticals Inc stock worth over $146,076 and over the last 12 years Jones sold SUPN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jones Bryan SUPN stock SEC Form 4 insiders trading

Jones has made over 3 trades of the Supernus Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Jones bought 4,700 units of SUPN stock worth $49,820 on 4 August 2017.

The largest trade Jones's ever made was exercising 6,712 units of Supernus Pharmaceuticals Inc stock on 30 March 2015 worth over $17,183. On average, Jones trades about 1,664 units every 108 days since 2013. As of 4 August 2017 Jones still owns at least 4,700 units of Supernus Pharmaceuticals Inc stock.

You can see the complete history of Jones Bryan stock trades at the bottom of the page.

What's Jones Bryan's mailing address?

Jones's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE, MD, 20850.

Insiders trading at Supernus Pharmaceuticals Inc

Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell, ePeter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.

What does Supernus Pharmaceuticals Inc do?

pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

Complete history of Jones Bryan stock trades at Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc executives and stock owners

Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jack Khattar,
  President, Chief Executive Officer, Secretary, Director
• Jack A. Khattar,
  Founder, Pres, CEO, Sec. & Director
• Stefan Schwabe,
  Executive Vice President - Research and Development, Chief Medical Officer
• Padmanabh Bhatt,
  Senior Vice President - Intellectual Property, Chief Scientific Officer
• Tami Martin,
  Senior Vice President - Regulatory Affairs
• Dr. Padmanabh P. Bhatt,
  Chief Scientific Officer & Sr. VP of Intellectual Property
• Tami T. Martin,
  Sr. VP of Regulatory Affairs
• Charles Newhall,
  Independent Chairman of the Board
• Frederick Hudson,
  Independent Director
• John Siebert,
  Independent Director
• Georges Gemayel,
  Independent Director
• Carrolee Barlow,
  Independent Director
• Frank Mottola,
  Senior Vice President, Quality, GMP Operations and Information Technology
• James Kelly,
  Chief Financial Officer, Executive Vice President
• Jeff Bozick,
  Sr. VP of Supply Chain
• Frank Mottola,
  Sr. VP of Quality, GMP Operations & Information Technology
• Kevin T. Anderson,
  Compliance Officer
• Timothy C. Dec,
  Sr. VP & CFO
• Dr. Jonathan Rubin,
  Sr. VP & Chief Medical Officer
• Dr. Bryan A. Roecklein,
  VP of Corp. Devel.
• Taylor Raiford,
  VP of Sales
• Dr. Todd Horich M.B.A., Ph.D.,
  VP of Marketing
• William A. Nuerge,
  Director
• M James Barrett,
  Director
• Victor Vaughn,
  Sr. VP of Sales
• Krishna Kittu Kolluri,
  10% owner
• Advisors Llcisaly Samuel Do...,
  
• Partners 11 Lp Nea,
  10% owner
• Forest Baskett,
  10% owner
• Michael Bigham,
  Director
• Peter J Barris,
  10% owner
• Enterprise Associates 11 Lp...,
  10% owner
• Scott D Sandell,
  10% owner
• Jones W. Bryan,
  VP of Business Development
• Management Ltd Abingworth,
  10% owner
• Advisors Llcorbimed Capital...,
  
• Michael B Sheffery,
  Director
• Gregory S Patrick,
  Sr. VP Chief Financial Officer
• Jonathan Rubin,
  SVP, Chief Medical Officer
• Timothy C Dec,
  Senior Vice-President & CFO
• Bethany Sensenig,
  Director